GlassScriptPhysician profile
Arthur Ryan Thompson
NPI 1215377932
$6,597.07
in general payments reported to CMS, 2019-2025
35 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $780 · 2021: $1,044 · 2022: $829 · 2023: $1,439 · 2024: $743 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.78 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,436.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $724.78 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $684.36 | 2019-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $650.67 | 2021-2025 | Rexulti |
| Abbvie INC. | $616.23 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $419.58 | 2019-2025 | Breztri, Farxiga |
| Esperion Therapeutics, INC. | $226.37 | 2020-2022 | |
| Glaxosmithkline, LLC. | $221.05 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $211.85 | 2019-2024 | Belsomra, Steglatro, Capvaxive |
| Pfizer INC. | $178.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.99 | 2019-2021 | |
| Exact Sciences Corporation | $125.80 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $116.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.76 | 2023-2025 | |
| Allergan, INC. | $100.73 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.91 | 2019-2022 | |
| Amarin Pharma, INC. | $78.46 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $57.78 | 2021-2022 | |
| Lilly USA, LLC | $49.45 | 2019-2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $41.38 | 2022-2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.79 | 2023 | Xifaxan, Trulance |
| Dynavax Technologies Corporation | $32.54 | 2021-2024 | Heplisav-B |
| Eisai INC. | $27.32 | 2021-2022 | |
| Genzyme Corporation | $25.69 | 2025 | |
| Horizon Therapeutics Plc | $25.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.17 | 2022 | |
| Boston Scientific Corporation | $16.83 | 2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Biogen, INC. | $16.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.18 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.70 | 2020 | |
| Almatica Pharma LLC | $13.37 | 2021 | |
| Hologic Sales and Service, LLC | $13.34 | 2021 | |
| Aytu Biopharma, INC. | $12.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.